BJDX vs. INVO, NMRD, SINT, NH, MOTS, QNRX, DYNT, TNON, AEMD, and IONM
Should you be buying Bluejay Diagnostics stock or one of its competitors? The main competitors of Bluejay Diagnostics include INVO Bioscience (INVO), Nemaura Medical (NMRD), Sintx Technologies (SINT), NantHealth (NH), Motus GI (MOTS), Quoin Pharmaceuticals (QNRX), Dynatronics (DYNT), Tenon Medical (TNON), Aethlon Medical (AEMD), and Assure (IONM). These companies are all part of the "medical" sector.
Bluejay Diagnostics (NASDAQ:BJDX) and INVO Bioscience (NASDAQ:INVO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and community ranking.
INVO Bioscience received 5 more outperform votes than Bluejay Diagnostics when rated by MarketBeat users. However, 66.67% of users gave Bluejay Diagnostics an outperform vote while only 46.67% of users gave INVO Bioscience an outperform vote.
In the previous week, Bluejay Diagnostics had 1 more articles in the media than INVO Bioscience. MarketBeat recorded 2 mentions for Bluejay Diagnostics and 1 mentions for INVO Bioscience. Bluejay Diagnostics' average media sentiment score of 0.50 beat INVO Bioscience's score of 0.00 indicating that Bluejay Diagnostics is being referred to more favorably in the media.
Bluejay Diagnostics has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, INVO Bioscience has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500.
18.5% of Bluejay Diagnostics shares are held by institutional investors. Comparatively, 12.0% of INVO Bioscience shares are held by institutional investors. 47.0% of Bluejay Diagnostics shares are held by company insiders. Comparatively, 3.5% of INVO Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Bluejay Diagnostics has a net margin of 0.00% compared to INVO Bioscience's net margin of -459.42%. INVO Bioscience's return on equity of 0.00% beat Bluejay Diagnostics' return on equity.
INVO Bioscience has higher revenue and earnings than Bluejay Diagnostics. INVO Bioscience is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.
Summary
Bluejay Diagnostics beats INVO Bioscience on 9 of the 15 factors compared between the two stocks.
Get Bluejay Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BJDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BJDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bluejay Diagnostics Competitors List
Related Companies and Tools
